Literature DB >> 8523520

A conserved LXXLF sequence is the major determinant in p6gag required for the incorporation of human immunodeficiency virus type 1 Vpr.

E Kondo1, H G Göttlinger.   

Abstract

The vpr gene product of human immunodeficiency virus type (HIV-1) is a virion-associated regulatory protein. A transferable virion association motif for Vpr is located in the p6 domain of the HIV-1 Gag polyprotein. To map the sequences in p6 that are involved in Vpr incorporation, we analyzed the ability of mutant forms of p6 to direct the incorporation of Vpr into chimeric viral particles. Our results show that the determinants which govern Vpr incorporation are largely confined to a C-terminal region of the p6 domain. Within this region, three hydrophobic residues in a highly conserved sequence motif (L-X-S-L-F-G) are absolutely required. Remarkably, the transfer of the conserved motif and of a single flanking residue to a heterologous Gag polyprotein was sufficient to transfer the ability to incorporate Vpr at moderate levels. The transfer of residues 32 to 46 of p6 led to Vpr incorporation levels that were comparable to those obtained with full-length HIV-1 Gag protein, indicating that this region contains essentially all the information required for efficient Vpr incorporation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8523520      PMCID: PMC189800     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  The human immunodeficiency virus type 2 vpr gene is essential for productive infection of human macrophages.

Authors:  N Hattori; F Michaels; K Fargnoli; L Marcon; R C Gallo; G Franchini
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

2.  Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release.

Authors:  H G Göttlinger; T Dorfman; J G Sodroski; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

3.  Human immunodeficiency virus vpr product is a virion-associated regulatory protein.

Authors:  E A Cohen; G Dehni; J G Sodroski; W A Haseltine
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

4.  Identification of HIV-1 vpr product and function.

Authors:  E A Cohen; E F Terwilliger; Y Jalinoos; J Proulx; J G Sodroski; W A Haseltine
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1990

5.  Mutational analysis of the human immunodeficiency virus vpr open reading frame.

Authors:  K Ogawa; R Shibata; T Kiyomasu; I Higuchi; Y Kishida; A Ishimoto; A Adachi
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

6.  High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis.

Authors:  B C Cunningham; J A Wells
Journal:  Science       Date:  1989-06-02       Impact factor: 47.728

7.  Rapid and efficient site-specific mutagenesis without phenotypic selection.

Authors:  T A Kunkel; J D Roberts; R A Zakour
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

8.  Mapping the CD4 binding site for human immunodeficiency virus by alanine-scanning mutagenesis.

Authors:  A Ashkenazi; L G Presta; S A Marsters; T R Camerato; K A Rosenthal; B M Fendly; D J Capon
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

9.  Human immunodeficiency virus vpr gene encodes a virion-associated protein.

Authors:  X Yuan; Z Matsuda; M Matsuda; M Essex; T H Lee
Journal:  AIDS Res Hum Retroviruses       Date:  1990-11       Impact factor: 2.205

10.  Rev activates expression of the human immunodeficiency virus type 1 vif and vpr gene products.

Authors:  E D Garrett; L S Tiley; B R Cullen
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

View more
  49 in total

1.  Nuclear export of human immunodeficiency virus type 1 Vpr is not required for virion packaging.

Authors:  Y Jenkins; P V Sanchez; B E Meyer; M H Malim
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

2.  Biochemical analyses of the interactions between human immunodeficiency virus type 1 Vpr and p6(Gag).

Authors:  Y Jenkins; O Pornillos; R L Rich; D G Myszka; W I Sundquist; M H Malim
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

3.  Integrase-lexA fusion proteins incorporated into human immunodeficiency virus type 1 that contains a catalytically inactive integrase gene are functional to mediate integration.

Authors:  M L Holmes-Son; S A Chow
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  Fitness costs limit viral escape from cytotoxic T lymphocytes at a structurally constrained epitope.

Authors:  Fred W Peyerl; Heidi S Bazick; Michael H Newberg; Dan H Barouch; Joseph Sodroski; Norman L Letvin
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

5.  Covalent modification of human immunodeficiency virus type 1 p6 by SUMO-1.

Authors:  Cagan Gurer; Lionel Berthoux; Jeremy Luban
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 6.  Integration site selection by retroviral vectors: molecular mechanism and clinical consequences.

Authors:  René Daniel; Johanna A Smith
Journal:  Hum Gene Ther       Date:  2008-06       Impact factor: 5.695

7.  Human immunodeficiency virus type 1 Nef incorporation into virions does not increase infectivity.

Authors:  Nadine Laguette; Serge Benichou; Stéphane Basmaciogullari
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

8.  Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain.

Authors:  M A Accola; B Strack; H G Göttlinger
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

9.  Interaction of the human immunodeficiency virus type 1 Vpr protein with the nuclear pore complex.

Authors:  R A Fouchier; B E Meyer; J H Simon; U Fischer; A V Albright; F González-Scarano; M H Malim
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

10.  Virion-targeted viral inactivation of human immunodeficiency virus type 1 by using Vpr fusion proteins.

Authors:  G P Kobinger; A Borsetti; Z Nie; J Mercier; N Daniel; H G Göttlinger; A Cohen
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.